Objectives: Polymicrobial bloodstream infection (BSI) is an imprecisely defined entity purportedly associated with a worse outcome than monomicrobial BSI. This study examines trends in BSI episodes caused by bacteria and Candida spp. (mixed-BSI) in a large teaching hospital.
Introduction
Bloodstream infections (BSIs) are a growing worldwide concern because of their potential for severe consequences. 1 Most BSIs are monomicrobial, but according to the largest series reported, polymicrobial BSI accounts for 6% -34% of BSIs. 2 -11 Polymicrobial BSI is usually a complication of serious local infection, mainly intra-abdominal, genitourinary or skin and soft tissue infection, and polymicrobial BSI (poly-BSI) is generally associated with a higher morbidity and more severe prognosis than monomicrobial BSI. 5, 11, 12 Microorganisms causing polymicrobial BSI are usually combinations of aerobic or facultative Grampositive and Gram-negative bacteria. 2,4 -6,8,11 -13 Candida spp. BSI (Candida-BSI) causes 3%-9% of all episodes of BSI in many hospitals and shows a rising tendency. 1, 9 Mixed bacteria and Candida spp. BSI (mixed-BSI), however, is a neglected entity of uncertain clinical significance. 14 This retrospective cohort study was designed to determine the incidence and trends of mixed-BSI episodes, describe the population at risk and assess whether the simultaneous presence of bacteraemia and candidaemia is associated with a worse prognosis, as compared with BSIs caused exclusively by Candida spp.
Methods

Setting
Our institution is a large teaching hospital that over the study period (2000-10) had 1550 beds. The institution has all the services of a general hospital with a very active surgery programme, including solid organ transplantation. It has three different adult intensive care units (ICUs) (medical, surgical and cardiac surgery) with a total of 42 beds and also a paediatric and a neonatal ICU.
Epidemiological study
We reviewed all BSI episodes occurring over the period 1 January 2000 to 31 December 2010, including data from all blood samples sent for culture to the microbiology department.
All data were entered into a database of significant BSI episodes that was maintained on a daily basis by a staff member of our department (M. R.-C.). This database contains the following information: patient identification, admitting department, dates of blood collection, number of blood cultures obtained, number of positive blood cultures, date of positivity and microorganisms identified. The incidence of BSI episodes per 1000 admissions was calculated as the number of episodes detected during the study period divided by the number of admissions over this period.
Retrospective cohort study
To examine clinical conditions, risk factors and prognosis in patients with mixed-BSI, we selected all adult patients with mixed-BSI from January 2006 to December 2010.
We chose the last 5 years of the study period in view of modifications made in the handling of candidaemic patients according to new treatment guidelines (e.g. Infectious Diseases Society of America 15 ). In this same period, and to control for the period effect, we chose a random simple sample (SPSS 15.0 software; SPSS, Chicago, IL, USA) of control patients with polymicrobial bacteraemia not including the isolation of yeasts [polybacterial BSI (polyB-BSI)] and a second control group of patients with Candida-BSI in whom concomitant bacterial BSI was excluded. The following information was obtained from the clinical records of the three groups of patients: sex; age; admitting department; severity of underlying conditions according to the McCabe-Jackson score 16 and age-corrected Charlson's comorbidity index; acquisition (community or nosocomial) and origin of BSI episode; severity of BSI; ICU admission; APACHE II score on admission to ICU; surgery in the preceding 30 days; number of antimicrobials and total defined daily doses (DDDs) per episode; and outcome, including in-hospital mortality, attributable mortality and length of ICU and hospital stay.
Blood culture systems
Blood cultures were processed using BACTEC 9240 (Becton Dickinson Microbiology Systems, NJ, USA). The sampling and transportation of blood cultures were performed according to standard procedures. We recommend the collection of three blood culture sets ( 10 mL each for adults) per episode of suspected bacteraemia. Blood from each extraction was placed in two vials containing aerobic and anaerobic media. All positive samples were subcultured and Gram stained. Standard methods were used to process positive blood cultures, to identify isolates and for antimicrobial susceptibility testing.
Definitions
Blood culture: a volume of blood obtained under aseptic conditions and used to inoculate two vials for the isolation of microorganisms.
BSI episode: episode of bacteraemia or fungaemia, referred only to patients and not to the number of blood cultures. All microorganisms isolated from the blood of the same patient within 1 week were considered responsible for a single episode, irrespective of whether the microorganisms came from the same or different blood culture bottles.
Contaminant microorganisms: the following microorganisms were categorized as probable contaminants unless proven otherwise: Bacillus spp., Corynebacterium spp. (except Corynebacterium jeikeium), Lactobacillus spp. and Propionibacterium spp. Coagulase-negative staphylococci and viridans group streptococci were considered probable pathogens only if recovered from two separate venepuncture samples. 17 Attributable mortality: mortality was considered attributable to the BSI if the patient died within 7 days of the onset of the bacteraemia, or whenever death occurred in the presence of persisting clinical sepsis or bacteraemia; otherwise, death was considered unrelated to the episode of bacteraemia.
Statistical analysis
To assess trends during the study period, we calculated the data for yearly intervals. To compare two or more proportions, such as the incidence of BSI/1000 admissions, we used the x 2 and linear trend tests. Categorical variables are provided with their frequency distributions. Continuous variables are summarized as medians and IQRs.
To analyse risk factors and prognosis, we used the median test for quantitative variables and the x 2 procedure or Fisher's exact test for qualitative variables.
To calculate BSI-attributable mortality, we calculated relative risks (RRs) and confidence intervals (CIs) at 95% for isolated variables and then fitted these to a logistical regression model in which the variables included were those showing a P value ,0.10.
For the three study groups (mixed-BSI, polyB-BSI and Candida-BSI), we also introduced the following variables in the model: sex, admitting department, acquisition, McCabe index, age-corrected Charlson's comorbidity index, surgery within the preceding 30 days, APACHE II, number of antimicrobials prescribed, and total DDDs per patient and episode. The RR was estimated by calculating predicted probabilities from the logistic function to give a coefficient of these probabilities. This coefficient is the RR. 18 All statistical tests were performed using SPSS 15.0 software (SPSS, Chicago, IL, USA). The level of significance was set at P,0.05.
Ethical considerations
The hospital Ethics Committee approved the study and waived informed consent.
Results
BSI and polymicrobial BSI
Over the study period (January 2000 to December 2010), our institution had 635721 admissions (mean, 57793 admissions/ year). From these patients, 451573 blood samples were cultured (710.3 blood cultures/1000 admissions).
Overall, we recorded 19 038 episodes of significant BSI in 16 467 patients (29.9 episodes/1000 admissions), increasing from 26.8/1000 admissions in 2000 to its peak value of 34.3/ 1000 admissions in 2009 (P,0.001) ( Table 1) .
Of all significant BSI episodes, 2001 were polymicrobial (poly-BSI) (10.5%). Poly-BSI occurred in 3.1 cases/1000 admissions. Trends in episodes of poly-BSI during the study period appear in Table 1 and Figure 1 . From 2000 to 2010, episodes increased by 19.4% (P ¼ 0.009).
Poly-BSI episodes were observed in very different units, mostly in the medical units (39%) followed by surgery departments (18%), ICU (17%), oncology-haematology (12%) and paediatrics (14%).
Overall, 84.7% of poly-BSI episodes involved two different microorganisms, 12.4% involved three and 3% involved four or more. The 4367 different microorganisms isolated in the 2001 episodes of poly-BSI are summarized in Figure 2 and 
Candidaemia
The numbers and proportions of BSI caused by Candida spp., with or without associated microorganisms, are shown in Figure 3 . Overall, we recorded 772 episodes of candidaemia (4.1% of all BSI episodes). Candidaemia was observed in 1.2 episodes/1000 admissions during the study period and this rate increased from 34 episodes in 2000 (0.7 episodes/1000 admissions) to 133 episodes in 2007 (2.0 episodes/1000 admissions) (P,0.001). Bacteria were also detected in 139 of the 772 candidaemic episodes (18.0%).
Mixed-BSI
The 139 episodes of mixed-BSI accounted for 0.7% of all BSI episodes, 6.9% of all poly-BSI and 18.0% of all episodes of candidaemia.
The incidence of mixed-BSI was 0.21/1000 admissions, increasing from 0.08 to 0.34 per 1000 admissions over the study period (P ¼0.007), meaning a 325% increase. Mixed-BSI represented 11.8% of all episodes of candidaemia in 2000 and rose to represent 22.9% in 2010.
Overall, mixed-BSI episodes affected patients admitted to medical departments (23, 16 .6%), surgical departments (11, 7.9%), ICUs (31, 22.3%), the oncology-haematology unit (19, 13.7%) and paediatrics (55, 39.6%; 51 in the neonatal ICU).
The number of bacterial species accompanying Candida spp. in the 139 episodes of mixed-BSI were: one bacterial species in 124 episodes (89.2%), two species in 13 (9.4%) and three or more species in 2 (1.4%). Besides the isolation of Candida spp., an extra non-Candida yeast species was identified in five of these episodes. The 301 microorganisms responsible for the mixed-BSI episodes are shown in Table 2 . Microorganisms accompanying Candida spp. were grouped as follows: Gram-positive aerobic or facultative bacteria in 88 episodes (63.3%); Gram-negative aerobic or facultative bacteria in 33 (23.7%); Gram-positive and Gram-negative aerobic or facultative bacteria in 9 (6.5%); and anaerobic bacteria in 9 (6.5%). The 144 yeasts isolated represented 47.8% of all microorganisms participating in mixed-BSI. The most frequent combinations of isolated microorganisms were as follows: Gram-positive cocci and yeasts, 59%; Gramnegative bacilli and yeasts, 26%; Gram-positive bacilli and yeasts, 4%; anaerobes and yeasts, 4%; and Gram-positive cocci and Gram-negative bacilli and yeasts, 7%.
Clinical manifestations, risk factors and prognosis
The main data for the three groups (54 patients each) selected for the case-control analysis are summarized in Table S1 (available as Supplementary data at JAC Online). The overall mortality was 42% and the attributable mortality was 27%. Univariate analysis indicated that compared with patients with polyB-BSI, those with mixed-BSI showed a lower rate of malignant disease, a more frequent in-hospital or intravenous catheter origin of BSI and less frequent intra-abdominal source, were more frequently admitted to an ICU, received more antimicrobials, had a longer in-hospital stay and had a higher mortality. When compared with patients with Candida-BSI, those with mixed-BSI had more severe underlying diseases according to McCabe-Jackson criteria, a higher APACHE II score, were more frequently admitted to an ICU or oncology-haematology unit, progressed more frequently to septic shock or multiorgan failure and received more antimicrobials. However, no significant differences in mortality could be detected. The origin of the BSIs is shown in Table S2 (available as Supplementary data at JAC Online).
By multivariate analysis, we compared patients who survived the BSI episode among the three groups. The results of this analysis (Table 3) revealed that the RR of attributable mortality of mixed-BSI compared with polyB-BSI was 1.76 (95% CI 1.57 -2.32, P¼ 0.036) and of mixed-BSI compared with Candida-BSI was 1.37 (95% CI 0.88-2.10, P ¼ 0.495). Therefore, no significant difference in attributable mortality was found in patients with mixed-BSI and Candida-BSI.
For all types of BSI, McCabe and APACHE II were independently associated with attributable mortality. Attributable mortality was 5.6 times higher (RR 5.64, 95% CI 1.75-18.12, P¼ 0.004) in patients with a rapidly fatal disease and with each APACHE II point gained, this mortality increased by 18% (P ¼ 0.007).
Discussion
Our findings indicate that mixed-BSI is an uncommon yet emergent disease. The lack of a commonly accepted definition makes it difficult to address the issue of poly-BSI. Some authors consider sequential episodes of monomicrobial bacteraemia occurring within 1 month or during the same infectious episode as polymicrobial episodes. 19 Others require the presence of more than one microorganism in the blood of a patient within a Mixed bacteraemia and candidaemia period that varies from 24 h to 1 week. 5,6,8,10,11,13,14,20 -22 Here, we considered as polymicrobial an episode in which more than one microorganism was isolated from the blood cultures taken to evaluate one episode of sepsis (within 1 week). Using this criterion, 10.7% of all our BSIs were polymicrobial, which is within the 6%-34.5% rate of poly-BSI reported in large series. However, despite no trends in poly-BSI reported recently, 2 -11 our data reveal a 30% increase in the incidence of poly-BSI in the last 10 years.
Poly-BSI occurs more frequently in elderly patients with multiple underlying diseases, and factors such as malignancy, corticosteroid therapy and recent hospitalization, parenteral nutrition, surgery and antimicrobial therapy predispose to the condition. 4 -6,8,10 -13 Although associated by some with a higher mortality than monomicrobial BSI, 5, 11, 12, 23 this view is not shared by all authors. 5, 14, 22, 24, 25 The main origins of poly-BSI are gastrointestinal (8%-24%) and genitourinary (5%-24%), although infections due to central venous catheters (3%-45%) seem to be increasing. 5,6,8,10 -13,19 As observed here, the most frequently isolated microorganisms are Gram-negative bacilli followed by streptococci and staphylococci. Anaerobes and fungi have been scarcely detected 5, 6, 11 and only a few papers have attributed a role in poly-BSI of specific microorganisms, including Pseudomonas spp. and Enterococcus spp. 26, 27 Overall, 17% of 248 episodes of Pseudomonas aeruginosa bacteraemia and 20% of episodes of enterococcal bacteraemia have been classified as polymicrobial, 26, 27 though Candida spp. have been rarely incriminated.
Candidaemia caused 4.1% of all our BSI episodes, which is within the 3%-9% reported in the literature and is associated with a high morbidity and mortality. 1,5,9,25,28 -30 Candidaemia is a monomicrobial disease; the isolation of more than one yeast species in blood samples (polyfungal candidaemia) is rare. 23,28,31 -33 Polyfungal candidaemia occurs in ,6% of episodes 23, 32, 33 and affects sicker patients. There are no data supporting a higher mortality of polyfungal than monomicrobial candidaemia.
The combined presence of bacteria and Candida spp. in the same poly-BSI episode has been rarely reported. However, in a recent paper by Klotz et al., 14 24% of candidaemic patients had synchronous bacteraemia. Other studies have reported that 1%-18% of candidaemia episodes are mixed-BSI. 2,4 -6,8,11,20 Despite these reports, trends in incidence and clinical manifestations of mixed-BSI have not been described. Our 139 cases of mixed-BSI represent 0.7% of all our BSIs, 6.9% of all 
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Mixed-BSI M-BSI/C-BSI (%) Figure 3 . Trends in the episodes of candidaemia and of the proportion of those episodes in which bacteria were also involved. M-BSI, mixed-BSI; C-BSI, Candida-BSI.
our poly-BSI and 18.0% of all our candidaemia episodes. According to our data, mixed-BSI is a growing problem, with a major incidence increase observed in terms of both episodes per 1000 admissions or percentage candidaemia episodes (14% in 2000 and 21% in 2010). This rise may be explained by the better detection of mixed-BSI infections with the use of current improved aerobic blood culture vials, which perform similarly to mycoses vials, 34 and by epidemiological changes, with an increasing number of patients with central venous catheters and of immunocompromised patients, at increased risk for a catheterrelated BSI. 35 Prevention strategies should be universally implemented and not only in ICUs. Notwithstanding, these figures may underestimate the problem of mixed-BSI infections, since blood cultures are insensitive to disseminated candidiasis, 36 perhaps through the bacterial inhibition of Candida spp. growth in blood cultures in mixed-BSI. 37 -39 A high proportion of our mixed-BSI were attributed a catheter origin. This feature of mixed-BSI is not observed in poly-BSI not involving Candida spp. Besides, the bacteria more frequently associated with Candida spp. in mixed-BSI are staphylococci and enterococci, and not Gram-negative microorganisms. 10, 12, 14 The clinical significance of mixed-BSI remains unclear. 12, 23 In a review of 13 cases of mixed-BSI, Verghese et al. 13 argued that mixed-BSI is a marker for a distinct population of critically ill surgical patients with a high overall mortality (78% in their study). In effect, mortality in our mixed-BSI patients was higher than in our patients with polyB-BSI. In a recent study by Kim et al., 24 comparing mixed-BSI with candidaemia, the authors found that mixed-BSI episodes had a less frequent clearance of the candidaemia within 3 days after initiation of antifungal therapy (63% versus 84%, P ¼ 0.035), yet they were not able to find any differences in treatment failure at 2 weeks, crude mortality at 6 weeks or survival through 100 days.
In our study, also compared with Candida-BSI, mixed-BSI presented in patients with a worse clinical situation and showed a more severe clinical course. This was so in the abovementioned study, with septic shock being 2.6 times more frequent in mixed-BSI episodes when compared with candidaemic episodes. 24 Nevertheless, differences in mortality were not significant either in the study by Kim et al. 24 or in our study, probably due to the small sample size. Mortality was independently related to the severity of underlying disease, as described by others for poly-BSI, 14, 15, 17, 21, 22, 25, 34 and to clinical severity on admission to the ICU.
In our model, we determined RRs rather than ORs. An RR is considered more appropriate when the outcome event is common (the incidence of attributable death was 27% among the patients included in the mortality analysis); in this situation, the OR overestimates the association. 18 The limitations of our study are that it is a single-centre study, it is of a retrospective nature and it examines risk factors and mortality only in adult patients. Besides, our sample size was small. However, a prospective study with a significant number of patients would take years.
In conclusion, mixed-BSI is rare, presents in high-risk patients and shows a higher mortality than poly-BSI caused by different bacteria. No significant differences were detected in mortality between mixed-BSI and candidaemia.
